open access

Vol 9, No 2 (2013)
Review paper
Published online: 2013-04-19
Get Citation

Economic evaluation of anti-cancer therapies — specific approach and challenges of clinical outcomes assessment in oncology

Rafał Zyśk, Maciej Niewada
Onkol. Prak. Klin 2013;9(2):42-54.

open access

Vol 9, No 2 (2013)
REVIEW ARTICLES
Published online: 2013-04-19

Abstract

The use of QALY (quality adjusted life years) metric to quantify clinical benefit in oncological settings is limited and
does not correspond with role and importance of QALY introduced with legal changes implemented in Poland
in 2012 by Reimbursement Act.
The authors compare different approaches to economic evaluation of anti-cancer therapy in Poland, UK, Canada,
Australia and Germany. The country were considered based on health technology assessment orientated reimbursement
system, specific approach applied for anti-cancer or end-of-life therapies and benchmarking in
recommendations issued by Agency of Health Technology Assessment in Poland. Following literature review the
key problems concerning QALY in the evaluation of antineoplastic treatments were defined, i.e. EQ-5D is relatively insensitive to changes in health status of cancer patients, limitations of health utility measurement in cancer, fixed
threshold of cost-effectiveness for all medical technologies regardless of disease specificity.

Abstract

The use of QALY (quality adjusted life years) metric to quantify clinical benefit in oncological settings is limited and
does not correspond with role and importance of QALY introduced with legal changes implemented in Poland
in 2012 by Reimbursement Act.
The authors compare different approaches to economic evaluation of anti-cancer therapy in Poland, UK, Canada,
Australia and Germany. The country were considered based on health technology assessment orientated reimbursement
system, specific approach applied for anti-cancer or end-of-life therapies and benchmarking in
recommendations issued by Agency of Health Technology Assessment in Poland. Following literature review the
key problems concerning QALY in the evaluation of antineoplastic treatments were defined, i.e. EQ-5D is relatively insensitive to changes in health status of cancer patients, limitations of health utility measurement in cancer, fixed
threshold of cost-effectiveness for all medical technologies regardless of disease specificity.
Get Citation

Keywords

QALY; quality-adjusted life years limitations; cost-effectiveness; cost-effectiveness threshold; reimbursement; drug policy; health technology assessment; health technology assessment; pharmacoeconomics

About this article
Title

Economic evaluation of anti-cancer therapies — specific approach and challenges of clinical outcomes assessment in oncology

Journal

Oncology in Clinical Practice

Issue

Vol 9, No 2 (2013)

Article type

Review paper

Pages

42-54

Published online

2013-04-19

Bibliographic record

Onkol. Prak. Klin 2013;9(2):42-54.

Keywords

QALY
quality-adjusted life years limitations
cost-effectiveness
cost-effectiveness threshold
reimbursement
drug policy
health technology assessment
health technology assessment
pharmacoeconomics

Authors

Rafał Zyśk
Maciej Niewada

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl